Although much more needs to be understood about the clinical utility of these subtypes, the implication for prostate cancer is that the heterogeneity of diabetes, specifically the contrasting pathophysiologies of obese and severe insulin resistant vs low BMI and insulin deficient phenotypes, may explain the obesity-related differences in associations between diabetes and prostate cancer outcomes. This evidence concerns the gene INS and prostate carcinoma.